Shanghai, China – 22 October, 2014 – La Fenice® Hypophyseal Hormone Infusion Pump ("La Fenice®"), an endocrinal management device of Shanghai MicroPort Medical (Group) Co ("MicroPort"), was recently awarded high-tech project by Science and Technology Commission of Shanghai Municipality.
La Fenice®, in-house developed by MicroPort's subsidiary Shanghai MicroPort Lifesciences Co, is designed for the treatment of Idiopathic Hypogonadotropic Hypogonadism ("IHH") which is also known as Kallmann Syndrome. In China, the incidence of IHH is 1/2000 in men and 1/10000 in women.
As the first domestically developed gonadotropin-releasing hormone ("GnRH") pulse pump, La Fenice® brings hope to many Chinese IHH patients. It works as an artificial hypothalamus – La Fenice® stimulates hypophysis to excrete follicle-stimulating hormone ("FSH") and luteinizing hormone ("LH") by simulating pulse excretion of human GnRH. In this way, it helps the development of the patient's secondary sex characters, enables him/her to regain sexuality and fertility, improves the bone mineral density and reduces the risk of cardiovascular diseases.
Currently, MicroPort has carried out clinical applications of our GnRH pulse pump in many influential hospitals across China.